MannKind Corporation (MNKD)

NASDAQ: MNKD · IEX Real-Time Price · USD
5.18
-0.11 (-2.08%)
Feb 3, 2023, 4:00 PM EST - Market closed
-2.08%
Market Cap 1.36B
Revenue (ttm) 76.23M
Net Income (ttm) -97.51M
Shares Out 263.20M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE 303.03
Dividend n/a
Ex-Dividend Date n/a
Volume 2,369,967
Open 5.20
Previous Close 5.29
Day's Range 5.15 - 5.33
52-Week Range 2.49 - 5.51
Beta 1.67
Analysts Buy
Price Target 6.22 (+20.08%)
Earnings Date Feb 23, 2023

About MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NR... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 28, 2004
Employees 348
Stock Exchange NASDAQ
Ticker Symbol MNKD
Full Company Profile

Financial Performance

In 2021, MannKind's revenue was $75.44 million, an increase of 15.81% compared to the previous year's $65.14 million. Losses were -$80.93 million, 41.4% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $6.22, which is an increase of 20.08% from the latest price.

Price Target
$6.22
(20.08% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pr...

1 week ago - GlobeNewsWire

MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pr...

1 week ago - GlobeNewsWire

6 Favorite Biotech Bets For 2023

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's...

Other symbols: AVXLAXNXNBIXSAVAVRTX
3 weeks ago - Forbes

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic ...

1 month ago - GlobeNewsWire

After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright

Is it a good or bad thing when a stock experiences a golden cross technical event?

2 months ago - Zacks Investment Research

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

WESTLAKE VILLAGE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices ...

3 months ago - GlobeNewsWire

MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 40% and 35.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

MannKind Corporation Reports 2022 Third Quarter Financial Results

Conference Call to Begin Today at 9:00 a.m. (ET) Conference Call to Begin Today at 9:00 a.m. (ET)

3 months ago - GlobeNewsWire

MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its manage...

3 months ago - GlobeNewsWire

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up

Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life chang...

Other symbols: BIAFKGCRIGUEC
4 months ago - InvestorPlace

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeuti...

4 months ago - GlobeNewsWire

7 Penny Stocks That Actually Have a Buy Rating

Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become.

Other symbols: AGENHYRENNDMTBLT
4 months ago - InvestorPlace

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p...

5 months ago - GlobeNewsWire

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeuti...

5 months ago - GlobeNewsWire

MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

MannKind Corporation Reports 2022 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET)

6 months ago - GlobeNewsWire

MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its manag...

6 months ago - GlobeNewsWire

MannKind Corporation to Participate in the BTIG Biotechnology Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic...

6 months ago - GlobeNewsWire

Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7

WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patie...

8 months ago - GlobeNewsWire

MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic ...

9 months ago - GlobeNewsWire

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro...

9 months ago - GlobeNewsWire

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products fo...

9 months ago - GlobeNewsWire

MannKind Corporation Participating at Upcoming Conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro...

9 months ago - GlobeNewsWire

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

MannKind Corporation Reports 2022 First Quarter Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) Conference Call to Begin Today at 5:00 p.m. (ET)

9 months ago - GlobeNewsWire